Literature DB >> 24719592

Zonisamide for weight loss in adolescents.

Mathew L Nguyen1, Mustafa H Pirzada1, Michael A Shapiro1.   

Abstract

Obesity in children and adolescents is a growing epidemic in the United States, and physicians are increasingly looking for safe and effective treatments. In recent years, pharmacologic treatment has been considered for severe and refractory cases of adolescent obesity. We present a case of an obese adolescent who presented to an inpatient psychiatric unit with a body mass index (BMI) of 37.8 (>98th percentile for age). He was started on zonisamide for the purposes of weight loss, and a steady decrease in weight and BMI was noted through 4 months of outpatient follow-up. During this time, the patient's weight decreased from 126.8 kg to 106.2 kg, a 20.6-kg loss, representing a 16.25% reduction in weight. His most recent BMI decreased to 31.7 (96th percentile for age). We discuss the potential use of zonisamide for weight loss in adolescents, considering the potential risks and benefits.

Entities:  

Keywords:  adolescents; antiobesity agents; obesity; weight loss; zonisamide

Year:  2013        PMID: 24719592      PMCID: PMC3979054          DOI: 10.5863/1551-6776-18.4.311

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  8 in total

1.  A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.

Authors:  Susan L McElroy; Erin Winstanley; Nicole Mori; Brian Martens; Jessica McCoy; Dianna Moeller; Anna I Guerdjikova; Paul E Keck
Journal:  J Clin Psychopharmacol       Date:  2012-04       Impact factor: 3.153

2.  Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.

Authors:  Kishore M Gadde; Mariko F Kopping; H Ryan Wagner; Gretchen M Yonish; David B Allison; George A Bray
Journal:  Arch Intern Med       Date:  2012-11-12

3.  Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients.

Authors:  JaeHyoung Lim; Young-Hoon Ko; Sook-Haeng Joe; Changsu Han; Moon-Soo Lee; Jaewon Yang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-07-22       Impact factor: 5.067

4.  Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010.

Authors:  Cynthia L Ogden; Margaret D Carroll; Brian K Kit; Katherine M Flegal
Journal:  JAMA       Date:  2012-01-17       Impact factor: 56.272

5.  The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy.

Authors:  J Wellmer; S Wellmer; J Bauer
Journal:  Acta Neurol Scand       Date:  2008-11-24       Impact factor: 3.209

6.  Zonisamide-induced weight loss in schizophrenia: case series.

Authors:  Jaewon Yang; Moon-Soo Lee; Sook-Haeng Joe; In-Kwa Jung; Seung-Hyun Kim
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

Review 7.  Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety.

Authors:  Sanjeev V Kothare; Joseph Kaleyias
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-04       Impact factor: 4.481

8.  Treatment of obesity in children and adolescents.

Authors:  Kelly L Matson; Renee M Fallon
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01
  8 in total
  3 in total

Review 1.  What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials.

Authors:  David J Heal; Jane Gosden
Journal:  Int J Obes (Lond)       Date:  2022-01-07       Impact factor: 5.551

2.  Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia.

Authors:  Anil Kakunje; Ashwini Prabhu; Sindhu Priya Es; Ravichandra Karkal; Rahyanath K Pookoth; Rekha Pd
Journal:  J Clin Psychopharmacol       Date:  2018-12       Impact factor: 3.153

Review 3.  Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.

Authors:  David J Heal; Sharon L Smith
Journal:  J Psychopharmacol       Date:  2021-07-28       Impact factor: 4.562

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.